纵向粪便钙卫蛋白特征揭示克罗恩病病程异质性
在爱丁堡IBD单元进行的回顾性队列研究,纳入356例新诊断克罗恩病患者及诊断后5年内2856次粪便钙卫蛋白测量,采用潜类别混合模型聚类,识别出4个特征性钙卫蛋白轨迹聚类,聚类归属与吸烟、上消化道受累及早期生物制剂治疗显著相关。
要点
- 新诊断克罗恩病患者诊断后5年内粪便钙卫蛋白纵向轨迹可聚为4个特征聚类。
- 聚类归属与吸烟(P=.015)、上消化道受累(P<.001)及早期生物制剂治疗(P<.001)显著相关。
- 组别轨迹不简单反映不同治疗方案,也不镜像经典疾病进展终点。
核心结论
- 分析展示了一种利用粪便钙卫蛋白刻画克罗恩病异质性的新方法。
- 组别轨迹不简单反映不同治疗方案,也不镜像经典疾病进展终点。
研究设计与样本
- 在爱丁堡IBD单元进行的回顾性队列研究,该单元为三级转诊中心。
- 使用潜类别混合模型对诊断后5年内观测到的粪便钙卫蛋白进行聚类。
- 研究队列包含356例新诊断克罗恩病患者和诊断后5年内2856次粪便钙卫蛋白测量(每例中位数7次)。
主要发现
- 识别出4个由特征性钙卫蛋白谱定义的聚类:一个持续高粪便钙卫蛋白聚类和3个具有不同纵向下降趋势的聚类。
- 聚类归属与吸烟显著相关(P=.015)。
- 聚类归属与上消化道受累显著相关(P<.001)。
- 聚类归属与早期生物制剂治疗显著相关(P<.001)。
关键数值与推荐
- 使用信息准则、冲积图和聚类轨迹决定最佳聚类数。
- 使用卡方检验、Fisher精确检验和方差分析检验与诊断时常用变量的关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The progressive nature of Crohn's disease is highly variable and hard to predict. In addition, symptoms correlate poorly with mucosal inflammation. There is therefore an urgent need to better characterize the heterogeneity of disease trajectories in Crohn's disease by utilizing objective markers of inflammation. We aimed to better understand this heterogeneity by clustering Crohn's disease patients with similar longitudinal fecal calprotectin profiles. METHODS: We performed a retrospective cohort study at the Edinburgh IBD Unit, a tertiary referral center, and used latent class mixed models to cluster Crohn's disease subjects using fecal calprotectin observed within 5 years of diagnosis. Information criteria, alluvial plots, and cluster trajectories were used to decide the optimal number of clusters. Chi-square test, Fisher's exact test, and analysis of variance were used to test for associations with variables commonly assessed at diagnosis. RESULTS: Our study cohort comprised 356 patients with newly diagnosed Crohn's disease and 2856 fecal calprotectin measurements taken within 5 years of diagnosis (median 7 per subject). Four distinct clusters were identified by characteristic calprotectin profiles: a cluster with consistently high fecal calprotectin and 3 clusters characterized by different downward longitudinal trends. Cluster membership was significantly associated with smoking (P = .015), upper gastrointestinal involvement (P < .001), and early biologic therapy (P < .001). CONCLUSIONS: Our analysis demonstrates a novel approach to characterizing the heterogeneity of Crohn's disease by using fecal calprotectin. The group profiles do not simply reflect different treatment regimens and do not mirror classical disease progression endpoints.
引用
- Constantine-Cooke N, Monterrubio-Gómez K, Plevris N, et al. Longitudinal Fecal Calprotectin Profiles Characterize Disease Course Heterogeneity in Crohn's Disease. Clin Gastroenterol Hepatol. 2023. PMID: 37004971. doi:10.1016/j.cgh.2023.03.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。